menu
    • menu
    [{"orgOrder":0,"company":"AbelZeta Pharma","sponsor":"AbelZeta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD20 CAR-T Cell","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"AbelZeta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbelZeta Pharma \/ AbelZeta Pharma","highestDevelopmentStatusID":"6","companyTruncated":"AbelZeta Pharma \/ AbelZeta Pharma"},{"orgOrder":0,"company":"AbelZeta Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"C-CAR168","moa":"Claudin 18.2","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"AbelZeta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbelZeta Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AbelZeta Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AbelZeta Pharma","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"C-TIL051","moa":"TIL","graph1":"Oncology","graph2":"Phase I","graph3":"AbelZeta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbelZeta Pharma \/ Nektar Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AbelZeta Pharma \/ Nektar Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by AbelZeta Pharma

    Menu

    AbelZeta Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbelZeta Pharma

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            AbelZeta Pharma

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-CAR168

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

                            Details : C-CAR168 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 20, 2025

                            Lead Product(s) : C-CAR168

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbelZeta Pharma

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            AbelZeta Pharma

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD20 CAR-T Cell

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : RenJi Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

                            Details : CD20 CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 08, 2024

                            Lead Product(s) : CD20 CAR-T Cell

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : RenJi Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbelZeta Pharma

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            AbelZeta Pharma

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C-TIL051

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Nektar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            C-TIL051 in Non-Small Cell Lung Cancer

                            Details : C-TIL051 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 09, 2023

                            Lead Product(s) : C-TIL051

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Nektar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth